Announcements Trials
Browse Landscape

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 52Observational 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 1Neuroendocrine Tumor Grade 3 1

Interventions

Surveys and Questionnaires 529Blood Specimen Collection 406Surgical Procedures, Operative 152Radiotherapy 131Interviews as Topic 131Drug Therapy 123Observation 122Magnetic Resonance Spectroscopy 104Biopsy 103Specimen Handling 70Data Collection 70Neoadjuvant Therapy 65Immunohistochemistry 64Magnetic Resonance Imaging 61Immune Checkpoint Inhibitors 59Watchful Waiting 52Immunotherapy 51Bevacizumab 50Positron Emission Tomography Computed Tomography 46Ultrasonography 44Hematologic Tests 42Liquid Biopsy 41Tomography, X-Ray Computed 40Therapeutics 40Radiosurgery 40Colonoscopy 40pembrolizumab 37Hepatectomy 37Gene Expression Profiling 36High-Energy Shock Waves 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Observational × surufatinib × Clear all
NCT07534371 2026-04-16

Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study

West China Hospital

Active not recruiting
500 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05973968 2023-08-04

Surufatinib in G3 Neuroendocrine Tumors

Qilu Hospital of Shandong University

Unknown
32 enrolled
EndocrineNET

Neuroendocrine Tumor Grade 3

Data powered by HemOnc (CC BY 4.0) Colophon âš¡